Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Gastroenterology

Journal Scan / Research · October 02, 2024

Efficacy and Safety of Bulevirtide Monotherapy Through 96 Weeks Among Patients With Chronic Hepatitis Delta Virus

Journal of Hepatology

 

Additional Info

Journal of Hepatology
Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial
J. Hepatol. 2024 Oct 01;81(4)621-629, H Wedemeyer, S Aleman, M Brunetto, A Blank, P Andreone, P Bogomolov, V Chulanov, N Mamonova, N Geyvandova, V Morozov, O Sagalova, T Stepanova, A Berger, S Ciesek, D Manuilov, RC Mercier, BL Da, GM Chee, M Li, JF Flaherty, AH Lau, A Osinusi, J Schulze Zur Wiesch, M Cornberg, S Zeuzem, P Lampertico

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading